Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Uncategorized Posts

    Targeting survivin as a potential new treatment for chondrosarcoma of bone

    January 4th, 2022

    Targeting survivin as a potential new treatment for chondrosarcoma of bone

    Y de Jong,
    J G van Oosterwijk,
    A B Kruisselbrink,
    I H Briaire-de Bruijn,
    G Agrogiannis,
    Z Baranski,
    A H G Cleven,
    A-M Cleton-Jansen,
    B van de Water,
    E H J Danen &
    J V…

    Read Article

    Bone and Soft Tissue Pathology Education


    Happy New Year!

    Another new set of 8 teaching cases has been uploaded to the Johns Hopkins Bone and Soft Tissue Pathology Teaching Website (https://apps.pathology.jhu.edu/bone/). Please note that previous difficulties accessing…

    Read Article

    Chondrosarcoma Awareness Day: Petition to Increase Research and Clinical Trials

    January 3rd, 2022

    Read Article

    Chordoma and Chondrosarcoma of the Skull Base Literature Review

    January 1st, 2022

    Chordoma and Chondrosarcoma of the Skull Base.pdf

    Read Article

    Your Support Saves Lives: Help Us Build A Chondrosarcoma Patient Registry

    December 31st, 2021

    Our GoFundMe is still live! The CS Foundation is committed to improving the treatment of patients living with this rare bone & soft tissue cancer. We are currently raising money for the development of a Patient Registry & Natural History…

    Read Article

    Johns Hopkins Bone Pathology Cases

    December 22nd, 2021

    This is a website we have created geared for educational purposes in bone and soft tissue pathology. A new series of videos that have been uploaded to the site. Will be making multiple videos covering everything you could ever want to know about…

    Read Article

    Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

    December 5th, 2021

    – Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma
    – Preliminary median progression-free survival (PFS) of 7.4 months and disease control rate of 89% observed in conventional chondrosarcoma…

    Read Article

    A Genetic Model for Central Chondrosarcoma Evolution Correlates with Patient Outcome

    November 23rd, 2021

    View ORCID ProfileWilliam Cross, Iben Lyskjær, Tom Lesluyes, Steven Hargreaves, Anna-Christina Strobl, Christopher Davies,

    Sara Waise, Shadi Hames, Dahmane Oukrif, Hongtao Ye, Fernanda Amary, Roberto Tirabosco, Toby Baker,

    David Barnes,…

    Read Article

    Chondrosarcoma Foundation Initiates a Fund-Raising Drive to Create a Patient Registry to Promote Research and Improve Care

    November 22nd, 2021

    In our on-going effort to promote more research, clinical trials, improve treatment and seek a cure for Chondrosarcoma, the CS Foundation is in the process of establishing a contractual partnership with NORD: National Organization for Rare Disorders…

    Read Article

    Cold Atmospheric Plasma Treatment of Chondrosarcoma Cells Affects Proliferation and Cell Membrane Permeability

    November 21st, 2021

    by Lyubomir Haralambiev
    1,2,*, Andreas Nitsch
    1, Josephine M. Jacoby
    1, Silas Strakeljahn
    1, Sander Bekeschus
    3, Alexander Mustea
    4, Axel Ekkernkamp
    1,2 and Matthias B. Stope
    4
    1
    Department of Trauma, Reconstructive Surgery and Rehabilitation…

    Read Article